https://healthtimesrhodeisland.com/article/906159985-new-preclinical-data-on-stx-1-a-first-in-class-senolytic-adc-to-be-presented-at-aacr-2026 Health Times of Rhode Island en PressRelease 2026-04-16T19:00:00+00:00 New Preclinical Data on STX-1, a First-in-Class Senolytic ADC, To Be Presented at AACR 2026 https://ml-eu.globenewswire.com/media/759246b4-e94a-4390-9310-5992d066d0fd/small/starkage-2-1-png.png https://healthtimesrhodeisland.com/article/906161358-un-nouveau-partenariat-pour-acc-l-rer-la-recherche-innovante-dans-le-domaine-r-nal Health Times of Rhode Island en PressRelease 2026-04-16T18:52:58+00:00 Un nouveau partenariat pour accélérer la recherche innovante dans le domaine rénal https://ml.globenewswire.com/media/YWQxMzkxODUtMGVmMC00MjViLWE0YzktNzYzMjU4ZTg0Nzc2LTUwMDE1OTA4My0yMDI2LTA0LTE2LWZy/tiny/The-Kidney-Foundation-of-Canad.png https://healthtimesrhodeisland.com/article/906161336-new-partnership-to-accelerate-innovation-in-kidney-research Health Times of Rhode Island en PressRelease 2026-04-16T18:52:30+00:00 New Partnership to Accelerate Innovation in Kidney Research https://ml.globenewswire.com/media/72e7ad16-e1ed-44e9-a825-2f85325df0db/small/kf-logo-en-horz-jpg.jpg https://healthtimesrhodeisland.com/article/906159925-survey-of-correctional-facility-staff-monthly-opioid-treatment-shot-may-help-reduce-medication-misuse Health Times of Rhode Island en PressRelease 2026-04-16T18:30:00+00:00 Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse https://ml-eu.globenewswire.com/media/42de3285-90ea-4020-a3ad-25f71026b41a/small/indivior-logo-jpg.jpg https://healthtimesrhodeisland.com/article/906160482-new-national-platform-launches-to-bridge-the-gap-in-bereavement-care-introducing-griefsupportdirectory-com Health Times of Rhode Island en PressRelease 2026-04-16T18:00:00+00:00 New National Platform Launches to Bridge the Gap in Bereavement Care: Introducing GriefSupportDirectory.com https://pressranger.s3.us-west-1.amazonaws.com/3231614/GriefSupportDirectoryLOGO1200x1200.jpg https://healthtimesrhodeisland.com/article/906159879-ab-science-provides-an-update-on-its-clinical-development-program Health Times of Rhode Island en PressRelease 2026-04-16T17:20:13+00:00 AB Science provides an update on its clinical development program. https://ml-eu.globenewswire.com/media/90d86a0e-7ea1-47ab-99d9-69985fa76ce0/small/logo-jpg.jpg https://healthtimesrhodeisland.com/article/906159919-ab-science-fait-le-point-sur-son-programme-de-d-veloppement-clinique Health Times of Rhode Island en PressRelease 2026-04-16T17:20:13+00:00 AB Science fait le point sur son programme de développement clinique https://ml-eu.globenewswire.com/media/90d86a0e-7ea1-47ab-99d9-69985fa76ce0/small/ https://healthtimesrhodeisland.com/article/906160602-protoflow-claims-evaluated-the-high-potency-prostate-support-ingredients-for-day-night-relief Health Times of Rhode Island en PressRelease 2026-04-16T17:19:59+00:00 ProtoFlow Claims Evaluated: The High Potency Prostate Support Ingredients for Day & Night Relief https://zingfast.com/wp-content/uploads/2026/04/ProtoFlow.jpg https://healthtimesrhodeisland.com/article/906144199-somnee-smart-sleep-headband-claims-evaluated-does-it-work-wearable-tech-for-restorative-rest-support Health Times of Rhode Island en PressRelease 2026-04-16T17:16:16+00:00 Somnee Smart Sleep Headband Claims Evaluated: Does It Work? Wearable Tech for Restorative Rest Support https://zingfast.com/wp-content/uploads/2026/04/Somnee-Smart-Sleep-Headband.jpg https://healthtimesrhodeisland.com/article/906143976-wake-radiology-steps-up-to-the-plate-for-susan-g-komen-triangle-race-for-the-cure Health Times of Rhode Island en PressRelease 2026-04-16T17:12:38+00:00 Wake Radiology "Steps Up to the Plate" for Susan G. Komen Triangle Race for the Cure https://ml.globenewswire.com/media/b40944d2-76ce-4a2f-8f95-3517f45fb57b/small/wr-logo-2024-png.png https://healthtimesrhodeisland.com/article/906144157-air-europa-enhances-safety-on-board-by-incorporating-specialized-medical-assistance-during-flights Health Times of Rhode Island en PressRelease 2026-04-16T17:08:25+00:00 Air Europa Enhances Safety on Board by Incorporating Specialized Medical Assistance During Flights https://ml.globenewswire.com/media/ZjM3OTE4Y2MtZDViMy00ZTNiLTk3ZDYtNGExMDFmZGViYzExLTEyMzYwOTUtMjAyNi0wNC0xNi1lbg==/tiny/MedAire.png https://healthtimesrhodeisland.com/article/906139405-evaxion-concludes-annual-general-meeting Health Times of Rhode Island en PressRelease 2026-04-16T15:30:00+00:00 Evaxion concludes Annual General Meeting https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://healthtimesrhodeisland.com/article/906142443-diverge-health-adds-oakland-southfield-physicians-in-michigan-to-list-of-physician-organization-partners Health Times of Rhode Island en PressRelease 2026-04-16T15:18:50+00:00 Diverge Health adds Oakland Southfield Physicians in Michigan to List of Physician Organization Partners https://ml.globenewswire.com/media/1022b2c7-9fa0-4c07-b961-01fe372e9f57/small/simple-fc-4x-png.png https://healthtimesrhodeisland.com/article/906141067-the-infrastructure-play-hiding-in-plain-sight-across-cardiac-care Health Times of Rhode Island en PressRelease 2026-04-16T15:00:00+00:00 The Infrastructure Play Hiding in Plain Sight Across Cardiac Care https://ml.globenewswire.com/media/fa80d6c4-97b0-465a-b7f0-f79df6f8bc19/small/screenshot-2025-12-09-at-4-53-16-am-1-png.png https://healthtimesrhodeisland.com/article/906141456-baylor-genetics-to-showcase-the-impact-of-early-genome-sequencing-at-annual-plugs-summit Health Times of Rhode Island en PressRelease 2026-04-16T15:00:00+00:00 Baylor Genetics to Showcase the Impact of Early Genome Sequencing at Annual PLUGS Summit https://ml.globenewswire.com/media/598c9f7b-cb07-4177-8fb3-646230113338/small/baylor-genetics-logo-oct-2025-for-wire-jpg.jpg https://healthtimesrhodeisland.com/article/906119748-purisaki-berberine-patches-2026-effective-weight-loss-for-women-lose-12-lbs-per-month-read-benefits-ingredients-side-effects-lunch-in-usa Health Times of Rhode Island en PressRelease 2026-04-16T14:33:59+00:00 Purisaki Berberine Patches 2026 | Effective Weight Loss For Women Lose 12+ lbs per Month Read Benefits, Ingredients, Side Effects, Lunch in USA. https://ml-eu.globenewswire.com/Resource/Download/18cfe3d6-e158-41a8-94e9-e4c1461ac91f/purisaki-berberine-patches-side-effects.png https://healthtimesrhodeisland.com/article/906126405-confidential-care-to-provide-bravemind-virtual-reality-treatment-to-veterans Health Times of Rhode Island en PressRelease 2026-04-16T14:31:40+00:00 Confidential Care to Provide BraveMind Virtual Reality Treatment to Veterans https://ml.globenewswire.com/media/23de679e-d628-4baa-ad17-b340e439a04a/small/soldierstrong-logo.jpg https://healthtimesrhodeisland.com/article/906119888-hearing-aids-market-set-to-reach-14-42-billion-by-2030-marketsandmarkets Health Times of Rhode Island en PressRelease 2026-04-16T14:30:00+00:00 Hearing Aids Market Set to Reach $14.42 Billion by 2030 | MarketsandMarkets™ https://ml.globenewswire.com/media/afcc5182-4ae0-43a8-a965-4351d590b7ed/small/mnm-logo-tm-jpg-jpg.JPG https://healthtimesrhodeisland.com/article/906126291-omada-health-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-7-2026 Health Times of Rhode Island en PressRelease 2026-04-16T14:19:06+00:00 Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 https://ml.globenewswire.com/media/f60ce57f-1859-49c3-9423-9562cf46cb64/small/omada-horizontal-color-r-png.png https://healthtimesrhodeisland.com/article/906124099-nbpure-launches-at-target-marking-major-retail-expansion Health Times of Rhode Island en PressRelease 2026-04-16T14:11:00+00:00 NBPure Launches at Target, Marking Major Retail Expansion https://ml.globenewswire.com/media/55a96f57-fe05-4240-987f-0b7995245537/small/nbpure.png https://healthtimesrhodeisland.com/article/906119956-american-urological-association-releases-clinically-localized-prostate-cancer-guideline-amendment Health Times of Rhode Island en PressRelease 2026-04-16T14:03:00+00:00 American Urological Association Releases Clinically Localized Prostate Cancer Guideline Amendment https://ml.globenewswire.com/media/MTYwN2UwZTAtZGM4Yy00ZjMzLWFmOGUtMzE5ZTM4OWVmNGZhLTEyNzYxOTAtMjAyNi0wNC0xNi1lbg==/tiny/American-Urological-Associatio.png https://healthtimesrhodeisland.com/article/906125837-disability-insurance-resource-for-medical-residents-launches-after-record-2026-match Health Times of Rhode Island en PressRelease 2026-04-16T14:00:32+00:00 Disability Insurance Resource for Medical Residents Launches After Record 2026 Match https://ml.globenewswire.com/media/af288d65-9499-4cf3-9d5c-7dec110ca42e/medium/gsi-disability-insurance-eligibility-deadlines-milestones-ri.jpg https://healthtimesrhodeisland.com/article/906119616-ai-can-now-understand-health-signals-from-15-seconds-of-your-voice-including-type-2-diabetes-fatigue-and-stress Health Times of Rhode Island en PressRelease 2026-04-16T14:00:00+00:00 AI can now understand health signals from 15 seconds of your voice, including type 2 diabetes, fatigue and stress https://ml-eu.globenewswire.com/media/23b8317d-2d0f-4ae8-9f7d-6102f0046b06/small/sm-logo-sm-blue-4x-png.png https://healthtimesrhodeisland.com/article/906125794-nephros-expands-strategic-focus-in-greater-new-york-market-with-dedicated-regional-leadership Health Times of Rhode Island en PressRelease 2026-04-16T13:57:04+00:00 Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership https://ml.globenewswire.com/media/47f2ed6d-a81f-4174-a3eb-0a46a538285e/small/logo-png.png https://healthtimesrhodeisland.com/article/906119994-mapi-pharma-to-present-efficacy-edss-data-from-glatiramer-acetate-depot-long-acting-injection-studies-in-relapsing-forms-of-multiple-sclerosis-rms Health Times of Rhode Island en PressRelease 2026-04-16T13:30:00+00:00 Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) at AAN 2026 https://ml.globenewswire.com/media/a15e698a-0f26-4d44-bf6a-78b7ae34d25d/small/mapi-pharma-logo-png.png https://healthtimesrhodeisland.com/article/906124031-inspira-completes-commercial-deployment-of-its-ame-system-at-a-tier-1-u-s-defense-entity Health Times of Rhode Island en PressRelease 2026-04-16T13:21:00+00:00 Inspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://healthtimesrhodeisland.com/article/906121308-maia-biotechnology-activates-first-u-s-site-for-ongoing-international-phase-2-expansion-trial-of-novel-telomere-targeting-treatment-targeting Health Times of Rhode Island en PressRelease 2026-04-16T13:20:00+00:00 MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer https://ml.globenewswire.com/media/a53747c9-c908-4493-b907-21f72017c02c/small/maia-logo-png-teal-png.png https://healthtimesrhodeisland.com/article/906120593-myriad-genetics-to-deliver-six-abstracts-including-two-podiums-at-aacr-2026 Health Times of Rhode Island en PressRelease 2026-04-16T13:15:00+00:00 Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 https://ml.globenewswire.com/media/5cb679cf-5a10-4b95-8cf7-fd1d0b56721a/small/myriad-s-stacked-png.png https://healthtimesrhodeisland.com/article/906125626-nurexone-biologic-inc-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update Health Times of Rhode Island en PressRelease 2026-04-16T13:15:00+00:00 NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/1514c671-cc84-4bcb-82d7-b834fce40882/small/nurexone-logo-rebrand-large-png.png https://healthtimesrhodeisland.com/article/906125147-progyny-expands-access-to-fertility-and-women-s-health-with-industry-s-first-fully-insured-supplemental-plan Health Times of Rhode Island en PressRelease 2026-04-16T13:05:40+00:00 Progyny Expands Access to Fertility and Women’s Health with Industry’s First Fully Insured Supplemental Plan https://ml.globenewswire.com/media/1342dacd-99c3-4043-af8a-2fd5e9ea569f/small/progyny-203860-no-tag-png.png https://healthtimesrhodeisland.com/article/906119488-philips-receives-fda-510-k-clearance-for-verida-the-world-s-first-ai-powered-detector-based-spectral-ct-advancing-diagnostic-precision-across Health Times of Rhode Island en PressRelease 2026-04-16T13:00:00+00:00 Philips receives FDA 510(k) clearance for Verida, the world’s first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications https://ml-eu.globenewswire.com/media/e5826782-01bc-45e7-b448-9ca1eae0125e/small/philips-logo-logotype-emblem-700x128-png.png https://healthtimesrhodeisland.com/article/906120654-retailers-nationwide-partner-with-muscular-dystrophy-association-to-send-hundreds-of-young-people-to-life-changing-summer-camp Health Times of Rhode Island en PressRelease 2026-04-16T13:00:00+00:00 Retailers Nationwide Partner with Muscular Dystrophy Association to Send Hundreds of Young People to Life-Changing Summer Camp https://ml.globenewswire.com/media/MjRkZDQ0MTAtMmFjNy00MTg3LTljZTItODA3ZGE5YzRiYWQwLTEwOTg0NjYtMjAyNi0wNC0xNi1lbg==/tiny/Muscular-Dystrophy-Association.png https://healthtimesrhodeisland.com/article/906120666-nearly-4-in-10-women-are-missing-vaginal-bacteria-linked-to-fertility Health Times of Rhode Island en PressRelease 2026-04-16T13:00:00+00:00 Nearly 4 in 10 women are missing vaginal bacteria linked to fertility https://ml.globenewswire.com/media/2937848e-5793-4af9-9eee-96eeeaf1cd51/medium/tiny-health-fertility-concerns-condition-association.png https://healthtimesrhodeisland.com/article/906120678-aim-immunotech-enters-pivotal-value-inflection-phase-with-planned-phase-3-study-of-ampligen-in-pancreatic-cancer-backed-by-positive-clinical Health Times of Rhode Island en PressRelease 2026-04-16T13:00:00+00:00 AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP https://ml.globenewswire.com/media/8e85b83b-047f-4f99-9c51-1aa232ffe9bb/small/aimlogo-jpg.jpg https://healthtimesrhodeisland.com/article/906120688-envue-issues-stockholder-letter-provides-corporate-update Health Times of Rhode Island en PressRelease 2026-04-16T13:00:00+00:00 ENvue Issues Stockholder Letter & Provides Corporate Update https://ml.globenewswire.com/media/e0a97028-a7c3-4dd6-a13f-a55e43617883/small/logo-small-722-jpg.jpg https://healthtimesrhodeisland.com/article/906121533-femasys-drives-international-growth-with-israeli-market-entry-for-fertility-portfolio Health Times of Rhode Island en PressRelease 2026-04-16T13:00:00+00:00 Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio https://ml.globenewswire.com/media/c668c3db-ff7f-4eb5-b51a-b8db25e838b4/small/femasys-logo-2-jpg.jpg https://healthtimesrhodeisland.com/article/906122343-fate-therapeutics-announces-data-presentation-of-ft839-next-generation-off-the-shelf-car-t-cell-product-candidate-for-the-broad-treatment-of Health Times of Rhode Island en PressRelease 2026-04-16T13:00:00+00:00 Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR… https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://healthtimesrhodeisland.com/article/906125037-achieve-life-sciences-announces-appointment-of-andrew-d-goldberg-md-as-chief-executive-officer-and-to-the-board-of-directors Health Times of Rhode Island en PressRelease 2026-04-16T12:57:06+00:00 Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors https://ml.globenewswire.com/media/1026e030-275c-4391-8f9a-65c5c1ec7b88/small/achieve-logo-717x800px-2-1-jpg.jpg https://healthtimesrhodeisland.com/article/906124768-achieve-life-sciences-announces-up-to-354-million-private-placement Health Times of Rhode Island en PressRelease 2026-04-16T12:53:49+00:00 Achieve Life Sciences Announces Up to $354 Million Private Placement https://ml.globenewswire.com/media/1026e030-275c-4391-8f9a-65c5c1ec7b88/small/achieve-logo-717x800px-2-1-jpg.jpg https://healthtimesrhodeisland.com/article/906121350-palisade-bio-announces-abstract-selected-for-poster-presentation-at-digestive-disease-week-ddw-2026 Health Times of Rhode Island en PressRelease 2026-04-16T12:50:00+00:00 Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 https://ml.globenewswire.com/media/0beaede8-1c7c-4f77-84a7-b1efd54c343c/small/logo-png.png https://healthtimesrhodeisland.com/article/906121174-blood-cancer-patients-and-their-supporters-cycle-across-iceland-to-raise-funds-and-awareness-for-multiple-myeloma-and-the-international-myeloma Health Times of Rhode Island en PressRelease 2026-04-16T12:45:00+00:00 Blood Cancer Patients and Their Supporters Cycle Across Iceland to Raise Funds and Awareness for Multiple Myeloma and the International Myeloma Foundation’s Research https://ml.globenewswire.com/media/f70068f9-568b-4858-8283-3c96a2db91d6/small/imf-logo-png.png https://healthtimesrhodeisland.com/article/906107105-profound-medical-to-release-first-quarter-2026-financial-results-on-may-7-conference-call-to-follow Health Times of Rhode Island en PressRelease 2026-04-16T12:37:49+00:00 Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow https://ml.globenewswire.com/media/94d9e057-9de3-430c-9a19-b41ff3e06a1e/small/profound-logo-cmyk-copy-jpg.jpg https://healthtimesrhodeisland.com/article/906102154-nanox-arc-x-digital-advanced-3d-imaging-built-for-access-and-powered-by-innovation-wins-2026-red-dot-award-for-product-design Health Times of Rhode Island en PressRelease 2026-04-16T12:35:00+00:00 Nanox.ARC X Digital Advanced 3D imaging built for access and powered by innovation Wins 2026 Red Dot Award for Product Design https://ml-eu.globenewswire.com/media/7a1764f8-84e3-4b28-ae23-9add5d57c378/small/nanox-logo-4-png.png https://healthtimesrhodeisland.com/article/906103685-srx-health-solutions-acquires-shares-of-compass-inc-and-increases-investment-in-opendoor-technologies-inc Health Times of Rhode Island en PressRelease 2026-04-16T12:30:00+00:00 SRx Health Solutions Acquires Shares of Compass Inc. and Increases Investment in Opendoor Technologies Inc. https://ml.globenewswire.com/media/768807fe-a29b-48f5-be44-977c8eaf49f0/small/srxlogo-jpg.jpg https://healthtimesrhodeisland.com/article/906105170-oncotelic-therapeutics-reports-fy-2025-results-highlighting-249m-net-income-and-jv-pipeline-progress Health Times of Rhode Island en PressRelease 2026-04-16T12:30:00+00:00 Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress https://ml.globenewswire.com/media/aa650511-a1c3-496e-803a-448d7f8d409a/small/picture1-jpg.jpg https://healthtimesrhodeisland.com/article/906105236-cdt-expands-multi-pathway-value-creation-strategy-across-pharma-ip-and-ai-driven-discovery Health Times of Rhode Island en PressRelease 2026-04-16T12:30:00+00:00 CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery https://ml.globenewswire.com/media/YWExMmUwYzEtOTJmZS00OGQ5LWE3OTgtZTI3ZTljZWZhMWMwLTEyNzQxMDItMjAyNi0wNC0xNi1lbg==/tiny/CDT-Equity-Inc-.png https://healthtimesrhodeisland.com/article/906103812-biomerica-announces-medicare-administrative-contractor-confirmation-of-individual-claim-review-for-infoods-ibs-opening-a-scalable-medicare Health Times of Rhode Island en PressRelease 2026-04-16T12:19:00+00:00 Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway https://ml.globenewswire.com/media/3461b9f0-3e95-484f-96e9-71608fc20239/small/biomerica-png.png https://healthtimesrhodeisland.com/article/906102165-ardelyx-to-report-first-quarter-2026-financial-results-on-april-30-2026 Health Times of Rhode Island en PressRelease 2026-04-16T12:01:00+00:00 Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 https://ml.globenewswire.com/media/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2/small/ardelyx-logo-rgb-jpg.jpg https://healthtimesrhodeisland.com/article/906101366-helsinn-appoints-giacomo-braglia-to-the-board-of-directors Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Helsinn appoints Giacomo Braglia to the Board of Directors https://ml-eu.globenewswire.com/media/5159c168-3b3f-444e-bbee-456218d74062/small/helsinn-logo-h-helsinn-blue-and-grey-1-png.png https://healthtimesrhodeisland.com/article/906101697-dr-falk-pharma-and-renexxion-announce-late-breaker-oral-presentation-of-global-phase-2b-gastroparesis-results-at-digestive-disease-week-ddw-2026 Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026 https://ml-eu.globenewswire.com/media/540f0a78-db35-42ad-9e90-7b81e8ff3ad6/small/renirl-logo-png.png https://healthtimesrhodeisland.com/article/906102052-inmune-bio-inc-announces-new-preclinical-data-at-aacr-2026-demonstrating-inb03-xpro1595-overcomes-resistance-and-reduces-metastases-in Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models https://ml.globenewswire.com/media/64035ec0-9fc2-414d-a693-27f1b1e90a31/small/logo-png.png https://healthtimesrhodeisland.com/article/906102244-pacira-to-report-first-quarter-2026-financial-results-on-thursday-april-30-2026 Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026 https://ml.globenewswire.com/media/3e502c92-e576-46b6-b602-a177ab0f5044/small/pacira-biosciences-tm-logo-rgb-v2025-300dpi-adj-png.png https://healthtimesrhodeisland.com/article/906102524-wellcome-leap-announces-2-million-prize-in-50-million-quantum-for-bio-challenge-program Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Wellcome Leap Announces $2 Million Prize in $50 Million Quantum for Bio Challenge Program https://ml.globenewswire.com/media/d87a734a-b034-417e-9ad6-0e7fd105fd33/small/leaplogo-blacktext-png.png https://healthtimesrhodeisland.com/article/906102574-aktis-oncology-appoints-industry-research-and-development-veteran-glenn-gormley-md-phd-to-its-board-of-directors Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://healthtimesrhodeisland.com/article/906102676-elicio-therapeutics-reports-inducement-grants Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Elicio Therapeutics Reports Inducement Grants https://ml.globenewswire.com/media/d588dddd-266e-4f3e-930a-d4c5ba15fe31/small/logo-jpg.jpg https://healthtimesrhodeisland.com/article/906103495-mimedx-announces-restructuring-and-cost-reduction-initiative Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 MIMEDX Announces Restructuring and Cost Reduction Initiative https://ml.globenewswire.com/media/2a60ab36-4917-479c-b53a-4f2113ca347d/small/mimedx-png.png https://healthtimesrhodeisland.com/article/906103530-vtak-definitive-agreement-to-acquire-100-of-fly-flyte-inc-obtains-shareholder-approval Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 VTAK Definitive Agreement to Acquire 100% of Fly Flyte Inc. Obtains Shareholder Approval https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://healthtimesrhodeisland.com/article/906103650-totus-medicines-to-present-first-in-class-covalent-irf5-inhibitor-data-at-aai-immunology2026 Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Totus Medicines to Present First-in-Class Covalent IRF5 Inhibitor Data at AAI IMMUNOLOGY2026 https://ml.globenewswire.com/media/3eba21cf-0a86-45b2-a9f6-405a8ffbe407/small/totus-modularlogo-orange-01-50-jpg.jpg https://healthtimesrhodeisland.com/article/906104085-prime-medicine-appoints-svetlana-makhni-as-chief-financial-officer Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer https://ml.globenewswire.com/media/ebddcf3b-2b71-4df6-99e8-d07617d9e327/small/prime-medicine-logo-approved-color-png.png https://healthtimesrhodeisland.com/article/906105493-medera-receives-fda-fast-track-designation-for-gene-therapy-targeting-duchenne-muscular-dystrophy-associated-cardiomyopathy Health Times of Rhode Island en PressRelease 2026-04-16T12:00:00+00:00 Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy https://ml.globenewswire.com/media/914f089c-79de-4cef-91d3-3b50d6e15230/small/medera-simple-horizontal-jpg.jpg https://healthtimesrhodeisland.com/article/906100725-edap-to-announce-first-quarter-2026-financial-results-on-may-7-2026 Health Times of Rhode Island en PressRelease 2026-04-16T11:30:00+00:00 EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 https://ml-eu.globenewswire.com/media/ded19329-9645-4860-ac2d-bf3e2422b649/small/focalone-square-logo-drkblue-web-400-1-png.png https://healthtimesrhodeisland.com/article/906102624-xilio-therapeutics-appoints-cheryl-r-blanchard-ph-d-to-its-board-of-directors Health Times of Rhode Island en PressRelease 2026-04-16T11:30:00+00:00 Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors https://ml.globenewswire.com/media/7e55cc25-f46f-423c-bf2a-e77ebaf69665/small/xilio-full-clr-logo-cmyk-png.png https://healthtimesrhodeisland.com/article/906103456-paratek-pharmaceuticals-to-present-new-data-on-nuzyra-omadacycline-at-escmid-global-2026 Health Times of Rhode Island en PressRelease 2026-04-16T11:30:00+00:00 Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026 https://ml.globenewswire.com/media/d492c495-d69c-4507-95f7-5742d0fc1720/small/images-png.png https://healthtimesrhodeisland.com/article/906103772-korro-announces-oral-and-poster-presentations-at-upcoming-scientific-conferences Health Times of Rhode Island en PressRelease 2026-04-16T11:30:00+00:00 Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences https://ml.globenewswire.com/media/d49fc3c4-5cf6-4b89-8434-2eadfff25c26/small/korro-logo-rgb-jpg.jpg https://healthtimesrhodeisland.com/article/906104100-helus-pharma-strengthens-medical-leadership-by-appointing-dr-ken-kramer-as-senior-vice-president-medical-affairs Health Times of Rhode Island en PressRelease 2026-04-16T11:30:00+00:00 Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs https://ml.globenewswire.com/media/575a4e81-a546-4d83-a092-e8f0df765900/small/hp-pms-with-margins-png.png https://healthtimesrhodeisland.com/article/906103698-kane-biotech-presents-revyve-clinical-data-at-symposium-on-advanced-wound-care-sawc-spring-conference Health Times of Rhode Island en PressRelease 2026-04-16T11:25:00+00:00 Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference https://ml.globenewswire.com/media/a7606fbc-273a-4100-a03b-cc73a0d8cd61/medium/thermoreversibility-of-us-fda-510k-cleared-revyve-antimicrob.jpg https://healthtimesrhodeisland.com/article/906104048-alterity-therapeutics-announces-late-breaker-oral-presentation-at-the-american-academy-of-neurology-annual-meeting Health Times of Rhode Island en PressRelease 2026-04-16T11:25:00+00:00 Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting https://ml.globenewswire.com/media/0771a9a2-2ac1-4a63-9767-a2b1df74af27/small/alterity-png.png https://healthtimesrhodeisland.com/article/906105594-meiragtx-announces-the-acquisition-of-botaretigene-sparoparvovec-bota-vec-for-the-treatment-of-x-linked-retinitis-pigmentosa-xlrp Health Times of Rhode Island en PressRelease 2026-04-16T11:10:00+00:00 MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) https://ml.globenewswire.com/media/6b45b8d0-975e-494b-8a46-b88360aa1791/small/mgx-logo-png.png https://healthtimesrhodeisland.com/article/906100791-beamion-lung-1-study-results-for-zongertinib-in-treatment-na-ve-patients-with-her2-mutant-advanced-nsclc-published-in-the-new-england-journal-of Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://healthtimesrhodeisland.com/article/906101058-radiopharm-theranostics-completes-enrollment-in-u-s-phase-2b-imaging-trial-of-rad-101-for-diagnosis-of-brain-metastases Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases https://ml-eu.globenewswire.com/media/8e246920-183e-46a4-b13c-a3c9ec50ada9/small/radx-logo-png.png https://healthtimesrhodeisland.com/article/906102193-marvel-biosciences-identifies-liquid-formulations-for-neurodevelopmental-disorders Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders https://ml.globenewswire.com/media/d49e32dc-88d9-4694-a3dd-6e663548e80d/small/picture1-png.png https://healthtimesrhodeisland.com/article/906102476-soleo-health-appoints-joy-rowan-as-new-senior-vice-president-of-sales-to-drive-strategic-growth-initiatives Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://healthtimesrhodeisland.com/article/906102687-nula-therapeutics-launches-with-up-to-20-million-arpa-h-award-to-advance-a-new-class-of-medicines-targeting-the-nuclear-envelope-of-cells Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Nula Therapeutics Launches with up to $20 Million ARPA-H Award to Advance a New Class of Medicines Targeting the Nuclear Envelope of Cells https://ml.globenewswire.com/media/23e9dd6f-19b3-4a7d-b756-61a12889b5b6/small/nula-logoexploration-2026-black-png.png https://healthtimesrhodeisland.com/article/906103383-remedy-plan-therapeutics-announces-multiple-presentations-at-the-aacr-annual-meeting-2026 Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Remedy Plan Therapeutics Announces Multiple Presentations at the AACR Annual Meeting 2026 https://ml.globenewswire.com/media/806541d7-639c-47b8-80fd-3a6fba5ced55/small/full-name-logo-png.png https://healthtimesrhodeisland.com/article/906103514-metagenomi-therapeutics-inc-announces-publication-in-nature-structural-molecular-biology-highlighting-proprietary-compact-crispr-nuclease-with Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency https://ml.globenewswire.com/media/7680f6bf-0803-4567-93bd-b52fc13a7887/small/new-mgx-logo-png.png https://healthtimesrhodeisland.com/article/906105297-tiziana-life-sciences-announces-publication-of-positive-data-demonstrating-intranasal-anti-cd3-antibody-attenuates-long-covid-neuroinflammation-and Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function https://ml.globenewswire.com/media/991c340c-a083-4bcb-ad41-e7eea83f6f97/small/tiziana-logo-png.png https://healthtimesrhodeisland.com/article/906105388-harrow-announces-the-issuance-of-j-code-for-iopidine-1 Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Harrow Announces the Issuance of J-Code for IOPIDINE® 1% https://ml.globenewswire.com/media/8e0382bf-e00a-4591-87aa-4e90001aabea/small/bw-harrow-logo-cmyk-wtag-wr-jpg.jpg https://healthtimesrhodeisland.com/article/906105490-adlai-nortye-announces-150-0-million-private-placement-equity-financing Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 Adlai Nortye Announces $150.0 Million Private Placement Equity Financing https://ml.globenewswire.com/media/ecf64cce-0b8f-42c4-9a39-9780955f3747/small/adlai-nortye-logo-png.png https://healthtimesrhodeisland.com/article/906105530-meiragtx-announces-positive-three-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-late-radiation-induced Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia https://ml.globenewswire.com/media/6b45b8d0-975e-494b-8a46-b88360aa1791/small/mgx-logo-png.png https://healthtimesrhodeisland.com/article/906105606-atum-welcomes-gavin-barnard-ph-d-as-chief-scientific-officer Health Times of Rhode Island en PressRelease 2026-04-16T11:00:00+00:00 ATUM Welcomes Gavin Barnard, Ph.D., as Chief Scientific Officer https://pressranger.s3.us-west-1.amazonaws.com/3231287/GB-Photo3.jpg https://healthtimesrhodeisland.com/article/906102791-eton-pharmaceuticals-announces-cfo-succession-plan Health Times of Rhode Island en PressRelease 2026-04-16T10:50:00+00:00 Eton Pharmaceuticals Announces CFO Succession Plan https://ml.globenewswire.com/media/db07cafa-b35c-4d61-a1a1-d330caf67ad2/small/eton-logo-png.png https://healthtimesrhodeisland.com/article/906105588-aclarion-secures-u-s-patent-advancing-scalable-ai-driven-assessment-of-chronic-low-back-pain Health Times of Rhode Island en PressRelease 2026-04-16T10:47:04+00:00 Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://healthtimesrhodeisland.com/article/906080545-zymeworks-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-7-2026 Health Times of Rhode Island en PressRelease 2026-04-16T10:00:00+00:00 Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 https://ml.globenewswire.com/media/de376a45-7a16-49db-8ad4-65ff45472c90/small/zymeworks-logo-color-png.png https://healthtimesrhodeisland.com/article/906081149-aligos-therapeutics-enters-into-exclusive-license-deal-with-xiamen-amoytop-biotech-co-ltd-to-develop-and-commercialize-pevifoscorvir-sodium-in Health Times of Rhode Island en PressRelease 2026-04-16T10:00:00+00:00 Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection https://ml.globenewswire.com/media/03ffbe89-c47f-4f83-b51f-f13a572e2cd1/small/aligos-png.png https://healthtimesrhodeisland.com/article/906080014-aicuris-receives-fda-priority-review-for-pritelivir-nda-and-presents-new-phase-3-data-at-escmid-2026 Health Times of Rhode Island en PressRelease 2026-04-16T09:00:00+00:00 Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026 https://ml-eu.globenewswire.com/media/67af2a5c-0ad8-4b2b-96f0-8e7f95f0b69c/small/aicuris-logo-png.png https://healthtimesrhodeisland.com/article/906059312-alethio-therapeutics-unveils-atx-011-a-breakthrough-mutation-agnostic-antibody-for-treating-essential-thrombocythemia-a-c-2b-market-and Health Times of Rhode Island en PressRelease 2026-04-16T08:00:00+00:00 Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND https://ml-eu.globenewswire.com/media/feaff9af-2ee5-405f-a373-a186e7295932/medium/steve-r-coats-phd.jpg https://healthtimesrhodeisland.com/article/906059423-freya-biosciences-announces-positive-phase-1-first-in-human-data-with-fb301-for-ivf-related-embryo-implantation-failure Health Times of Rhode Island en PressRelease 2026-04-16T07:30:00+00:00 Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure https://ml-eu.globenewswire.com/media/eb134d70-d14e-4ab2-b457-0ccece26cf2f/small/freya-logo-png.png https://healthtimesrhodeisland.com/article/906059449-storm-therapeutics-secures-56-million-series-c-financing-and-doses-first-patient-in-phase-2-sarcoma-trial-of-stc-15 Health Times of Rhode Island en PressRelease 2026-04-16T07:00:00+00:00 STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15 https://ml-eu.globenewswire.com/media/1f159389-0c23-4305-b40e-b83e89274cee/small/logo-png.PNG https://healthtimesrhodeisland.com/article/906059547-atoss-unterst-tzt-charit-bei-der-workforce-management-modernisierung Health Times of Rhode Island en PressRelease 2026-04-16T07:00:00+00:00 ATOSS unterstützt Charité bei der Workforce Management-Modernisierung https://ml.globenewswire.com/media/24d8ce1e-5bd2-4407-bc66-97e358ca533c/medium/charite-wiebke-peitz.jpg https://healthtimesrhodeisland.com/article/906059589-cancervax-to-target-colorectal-cancer-following-recent-biodistribution-breakthroughs Health Times of Rhode Island en PressRelease 2026-04-16T07:00:00+00:00 CancerVax to Target Colorectal Cancer Following Recent Biodistribution Breakthroughs https://ml.globenewswire.com/media/c77c55dd-4af0-4572-8921-b0f75e9f72c2/small/logo-png.png https://healthtimesrhodeisland.com/article/906040433-greywolf-therapeutics-appoints-edwin-moses-as-chair Health Times of Rhode Island en PressRelease 2026-04-16T06:00:00+00:00 Greywolf Therapeutics appoints Edwin Moses as Chair https://ml-eu.globenewswire.com/media/969dca71-90d5-4199-ba27-14b8aac5ee6d/medium/dr-edwin-moses-portrait.jpeg https://healthtimesrhodeisland.com/article/906040834-onward-medical-successfully-raises-over-eur-40-million-in-capital-increase Health Times of Rhode Island en PressRelease 2026-04-16T05:30:00+00:00 ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase https://ml.globenewswire.com/media/a60261ec-0c66-4acb-8726-e567073990a2/small/onwardresized1-png.png https://healthtimesrhodeisland.com/article/906040574-bioversys-announces-first-patient-first-visit-in-habp-vabp-pivotal-phase-3-riv-target-trial-of-bv100 Health Times of Rhode Island en PressRelease 2026-04-16T05:00:00+00:00 BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100 https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://healthtimesrhodeisland.com/article/906001021-uroflow-claims-evaluated-reviewing-the-official-website-benefits-ingredients-to-support-prostate-health Health Times of Rhode Island en PressRelease 2026-04-16T01:36:43+00:00 UroFlow Claims Evaluated: Reviewing the Official Website Benefits & Ingredients to Support Prostate Health https://zingfast.com/wp-content/uploads/2026/04/UroFlow.jpg https://healthtimesrhodeisland.com/article/905966552-vivos-therapeutics-reports-full-year-2025-financial-results Health Times of Rhode Island en PressRelease 2026-04-15T20:20:00+00:00 Vivos Therapeutics Reports Full Year 2025 Financial Results https://ml.globenewswire.com/media/22d07f60-2e17-421d-bbc3-748c2402061e/small/picture2-jpg.JPG https://healthtimesrhodeisland.com/article/905968198-nexgel-reschedules-shareholder-update-conference-call-to-april-23rd-at-4-30-p-m-et-to-provide-update-on-celularity-transaction Health Times of Rhode Island en PressRelease 2026-04-15T20:12:00+00:00 NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction https://ml.globenewswire.com/media/0e76fff8-7aee-4b60-ba26-62dda9975939/small/logo-png.png https://healthtimesrhodeisland.com/article/905967719-teladoc-health-to-announce-first-quarter-2026-financial-results Health Times of Rhode Island en PressRelease 2026-04-15T20:05:00+00:00 Teladoc Health to Announce First Quarter 2026 Financial Results https://ml.globenewswire.com/media/439ced23-c1ca-477b-8607-8067a1777d11/small/tdh-logo-png.png https://healthtimesrhodeisland.com/article/905967914-adaptive-biotechnologies-to-report-first-quarter-2026-financial-results-on-may-5-2026 Health Times of Rhode Island en PressRelease 2026-04-15T20:05:00+00:00 Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 https://ml.globenewswire.com/media/6c319974-0bac-45f1-83d9-ae9987dfdf44/small/adpt-new-logo-jpg.jpg https://healthtimesrhodeisland.com/article/905966301-nkarta-announces-fda-agreement-on-outpatient-dosing-of-nkx019-in-autoimmune-disease-expanding-access-to-community-rheumatology-centers Health Times of Rhode Island en PressRelease 2026-04-15T20:01:00+00:00 Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers https://ml.globenewswire.com/media/09e7df7f-9555-45c9-bef1-86131c859ed3/small/nkarta-logo-2022-jpg.jpg https://healthtimesrhodeisland.com/article/905966438-anika-to-issue-first-quarter-2026-financial-results-on-wednesday-april-29-2026 Health Times of Rhode Island en PressRelease 2026-04-15T20:01:00+00:00 Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026 https://ml.globenewswire.com/media/342e50d9-f0e4-4e79-b568-840299c2045d/small/anika-new-logo-blue-1200x628-png.png https://healthtimesrhodeisland.com/article/905966946-wave-life-sciences-announces-proposed-redomiciliation-to-the-united-states Health Times of Rhode Island en PressRelease 2026-04-15T20:01:00+00:00 Wave Life Sciences Announces Proposed Redomiciliation to the United States https://ml.globenewswire.com/media/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0/small/wave-life-sciences-logo-jpg.jpg https://healthtimesrhodeisland.com/article/905967222-traws-pharma-reports-full-year-2025-results-and-provides-business-highlights Health Times of Rhode Island en PressRelease 2026-04-15T20:01:00+00:00 Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights https://ml.globenewswire.com/media/1eb1780a-724e-4555-ab4d-455e27d18544/small/traws-pharma-blue-png.png https://healthtimesrhodeisland.com/article/905967681-algernon-health-announces-effective-date-of-previously-announced-name-change-to-grey-matters-health-inc-and-its-10-1-share-consolidation Health Times of Rhode Island en PressRelease 2026-04-15T20:01:00+00:00 Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation https://ml.globenewswire.com/media/57ab3e9f-6614-45fb-863e-eb22d71c3d2a/small/picture1-jpg.jpg https://healthtimesrhodeisland.com/article/905966572-elion-therapeutics-announces-initiation-of-turletricin-el219-phase-2-study-in-invasive-mould-infection Health Times of Rhode Island en PressRelease 2026-04-15T20:00:00+00:00 Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection https://ml.globenewswire.com/media/4645f248-48c0-4a58-a2bd-f62e313e2b31/small/eliontx-logo-color-rgb-2-jpg.jpg https://healthtimesrhodeisland.com/article/905967917-arcutis-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-6-2026 Health Times of Rhode Island en PressRelease 2026-04-15T20:00:00+00:00 Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 https://ml.globenewswire.com/media/1b166f47-afb1-44f1-91be-2d73e97c0ec3/small/arcutis-logo-png.png https://healthtimesrhodeisland.com/article/905949618-the-association-for-frontotemporal-degeneration-aftd-hosts-first-capitol-hill-briefing-frontotemporal-degeneration-shining-a-light-on-a Health Times of Rhode Island en PressRelease 2026-04-15T19:20:27+00:00 The Association for Frontotemporal Degeneration (AFTD) Hosts First Capitol Hill Briefing: “Frontotemporal Degeneration: Shining a Light on a Little-Known Dementia” https://ml.globenewswire.com/media/OWJjOGJmOTctMmJmOC00NzExLTk5MTUtMmQ5N2EwNzBhZjk3LTEyNzYyMTctMjAyNi0wNC0xNS1lbg==/tiny/Association-for-Frontotemporal.png https://healthtimesrhodeisland.com/article/905949656-svetlana-mojsov-one-of-the-scientists-behind-ozempic-and-mathematician-carlos-kenig-who-decoded-laws-of-motion-honored-as-king-faisal-prize-2026 Health Times of Rhode Island en PressRelease 2026-04-15T19:19:26+00:00 Svetlana Mojsov, one of the Scientists behind Ozempic, and Mathematician Carlos Kenig, who Decoded Laws of Motion, Honored as King Faisal Prize 2026 Laureates https://ml.globenewswire.com/media/NTZiODI3YmYtZjVkZC00NTIyLTgzMmYtMTNiYTkzYTMxMTM4LTEyNTgxNjctMjAyNi0wNC0xNS1lbg==/tiny/King-Faisal-Prize.png https://healthtimesrhodeisland.com/article/905949203-shingles-raises-heart-and-stroke-risk-protect-yourself-with-vaccination Health Times of Rhode Island en PressRelease 2026-04-15T18:57:20+00:00 Shingles Raises Heart and Stroke Risk: Protect Yourself with Vaccination https://ml.globenewswire.com/Resource/Download/a116ab29-9104-48c4-bca2-d4435afdd0b3/17872-1.jpg https://healthtimesrhodeisland.com/article/905948978-running-with-purpose-nashville-podiatrist-dr-lanier-shares-expert-tips-for-injury-free-half-marathon-training Health Times of Rhode Island en PressRelease 2026-04-15T18:45:36+00:00 Running with Purpose: Nashville Podiatrist Dr. Lanier Shares Expert Tips for Injury-Free Half Marathon Training https://ml.globenewswire.com/media/55db2f5c-a3dc-4282-9eba-d32817e25477/medium/family-fitness-in-action.jpeg https://healthtimesrhodeisland.com/article/905947083-neutrolis-appoints-caren-deardorf-as-chief-business-strategy-officer Health Times of Rhode Island en PressRelease 2026-04-15T18:00:00+00:00 Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer https://ml.globenewswire.com/media/44cdba09-fdb9-4ee1-b7bf-1dcfe5784800/small/20180228-opr-or-logos-biz-wd-neutrolis-logo-1-jpg.jpg https://healthtimesrhodeisland.com/article/905933479-assureckd-appoints-former-lumiradx-technical-director-dr-aman-khan-as-chief-technology-officer-to-lead-diagnostic-platform-development Health Times of Rhode Island en PressRelease 2026-04-15T17:11:20+00:00 AssureCKD Appoints Former LumiraDx Technical Director Dr. Aman Khan as Chief Technology Officer to Lead Diagnostic Platform Development https://ml.globenewswire.com/media/MTI4MWJkOWEtNjkzNy00ZTYzLWI4OWMtZGZmNmRiMDA1N2ZiLTEzMjI2NjUtMjAyNi0wNC0xNS1lbg==/tiny/AssureCKD.png https://healthtimesrhodeisland.com/article/905930843-basilea-aktion-re-genehmigen-an-der-generalversammlung-2026-alle-antr-ge-des-verwaltungsrats Health Times of Rhode Island en PressRelease 2026-04-15T16:30:00+00:00 Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats https://ml-eu.globenewswire.com/media/4403c5ae-6c9a-43d2-8c5f-deb2de747a47/small/basilea-logo-jpg.jpg https://healthtimesrhodeisland.com/article/905931077-basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-2026-annual-general-meeting Health Times of Rhode Island en PressRelease 2026-04-15T16:30:00+00:00 Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting https://ml-eu.globenewswire.com/media/4403c5ae-6c9a-43d2-8c5f-deb2de747a47/small/basilea-logo-jpg.jpg https://healthtimesrhodeisland.com/article/905933265-onward-medical-launches-capital-increase-for-indicative-amount-of-eur-40-million Health Times of Rhode Island en PressRelease 2026-04-15T16:19:00+00:00 ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 40 Million https://ml.globenewswire.com/media/a60261ec-0c66-4acb-8726-e567073990a2/small/onwardresized1-png.png https://healthtimesrhodeisland.com/article/905932908-family-therapist-and-acclaimed-author-to-lead-webinar-on-healthy-co-parenting-boundaries Health Times of Rhode Island en PressRelease 2026-04-15T16:02:13+00:00 Family Therapist and Acclaimed Author to Lead Webinar on Healthy Co-Parenting Boundaries https://ml.globenewswire.com/media/N2RlYWJmOTktOWI0Mi00Nzg0LWJmM2QtZGRhZjgzM2QzYzMwLTEyNjU4MjMtMjAyNi0wNC0xNS1lbg==/tiny/TalkingParents.png https://healthtimesrhodeisland.com/article/905916881-inteleos-foundation-medmissions-2026 Health Times of Rhode Island en PressRelease 2026-04-15T15:33:54+00:00 Inteleos Foundation تعلن عن جائزة MedMissions لعام 2026 لتعزيز نطاق الوصول إلى خدمات التصوير بالموجات فوق الصوتية لصحة الأم في خمس دول https://ml.globenewswire.com/media/ZTdkYjEwNGQtYWUwMS00N2JkLTg5NzctYzg2NTgxOGY1MmQxLTEyNDUwMzItMjAyNi0wNC0xNS1hcg==/tiny/Inteleos-Inc-.png https://healthtimesrhodeisland.com/article/905916931-inteleos-foundation-annonce-les-laur-ats-du-prix-medmissions-2026-pour-renforcer-l-acc-s-l-chographie-maternelle-dans-cinq-nations Health Times of Rhode Island en PressRelease 2026-04-15T15:33:54+00:00 Inteleos Foundation annonce les lauréats du Prix MedMissions 2026 pour renforcer l’accès à l’échographie maternelle dans cinq nations https://ml.globenewswire.com/media/ZTdkYjEwNGQtYWUwMS00N2JkLTg5NzctYzg2NTgxOGY1MmQxLTEyNDUwMzItMjAyNi0wNC0xNS1mcg==/tiny/Inteleos-Inc-.png https://healthtimesrhodeisland.com/article/905913948-what-if-you-could-reboot-sick-cells Health Times of Rhode Island en PressRelease 2026-04-15T15:00:00+00:00 What if you could reboot sick cells? https://ml-eu.globenewswire.com/media/e93daf2c-fee9-4db8-8c09-bab3a01da23b/medium/targeted-mitochondrial-delivery.jpg https://healthtimesrhodeisland.com/article/905916100-cerene-by-channel-medsystems-partners-with-hey-girl-fund-to-support-menstrual-education-at-caregivers-girlies-brunch-on-saturday-april-18 Health Times of Rhode Island en PressRelease 2026-04-15T14:36:09+00:00 Cerene® by Channel Medsystems Partners with Hey Girl! Fund to Support Menstrual Education at Caregivers & Girlies Brunch on Saturday, April 18 https://ml.globenewswire.com/media/c8db1662-2442-4ba8-8910-6fe74312b2ee/small/channel-med-logo-1-jpg.jpg https://healthtimesrhodeisland.com/article/905915517-nexalin-advances-fda-alzheimer-s-strategy-following-landmark-leadership-meetings-in-the-u-s-and-china Health Times of Rhode Island en PressRelease 2026-04-15T14:00:00+00:00 Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China https://ml.globenewswire.com/media/7f481b55-16b6-4c8a-8356-30d54079a605/small/nexalin-jpg.jpg https://healthtimesrhodeisland.com/article/905898058-walking-yoga-app-how-combining-walking-and-yoga-accelerates-weight-loss Health Times of Rhode Island en PressRelease 2026-04-15T13:33:30+00:00 Walking Yoga App: How Combining Walking and Yoga Accelerates Weight Loss https://ml-eu.globenewswire.com/media/27e0ac34-ddfe-42a2-8a0b-7469fbf18c71/medium/walking-yoga-a-new-method-to-lose-weight.png https://healthtimesrhodeisland.com/article/905902021-avita-medical-founder-fiona-wood-honored-with-lifetime-achievement-award-by-american-burn-association Health Times of Rhode Island en PressRelease 2026-04-15T13:20:00+00:00 AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://healthtimesrhodeisland.com/article/905901742-polaryx-therapeutics-recognized-with-pinnacle-award-for-excellence-in-pediatric-care Health Times of Rhode Island en PressRelease 2026-04-15T13:15:00+00:00 Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care https://ml.globenewswire.com/media/64e2f507-40e8-46aa-b22e-6661e7035467/small/polaryx-logonew-png.png https://healthtimesrhodeisland.com/article/905903537-the-end-of-performance-at-any-cost-as-spider-silk-points-to-a-cleaner-future Health Times of Rhode Island en PressRelease 2026-04-15T13:15:00+00:00 The End of Performance at Any Cost, as Spider Silk Points to a Cleaner Future https://ml.globenewswire.com/media/NTA2YTQ4YmYtM2Q0Yy00YjkxLWIwZmYtYTNiZTk2YWRlMjYzLTUwMDE1MTA3NC0yMDI2LTA0LTE1LWVu/tiny/24-7-Market-News-and-Kraig-Lab.png https://healthtimesrhodeisland.com/article/905900906-pacbio-and-covaris-announce-joint-workflow-enabling-hifi-long-read-sequencing-of-ffpe-tumor-samples Health Times of Rhode Island en PressRelease 2026-04-15T13:05:00+00:00 PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples https://ml.globenewswire.com/media/f408d681-e68c-4113-a7cd-be24486deefc/small/logo-centered-440x386-png.png https://healthtimesrhodeisland.com/article/905901276-tango-therapeutics-announces-leadership-appointments-to-accelerate-late-stage-development-of-vopimetostat Health Times of Rhode Island en PressRelease 2026-04-15T13:05:00+00:00 Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat https://ml.globenewswire.com/media/d6e37a27-2e33-43bb-ae05-bfb0dedbf190/small/tango-logo-png.png https://healthtimesrhodeisland.com/article/905903439-prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform Health Times of Rhode Island en PressRelease 2026-04-15T13:05:00+00:00 ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform https://ml.globenewswire.com/media/c6222831-7e36-422c-99fd-dff03828dc3a/small/logo-jpg.jpg https://healthtimesrhodeisland.com/article/905903589-sienna-announces-april-dividend Health Times of Rhode Island en PressRelease 2026-04-15T13:00:23+00:00 Sienna Announces April Dividend https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://healthtimesrhodeisland.com/article/905897427-annual-general-meeting-of-kuros-biosciences-approves-all-resolutions Health Times of Rhode Island en PressRelease 2026-04-15T13:00:00+00:00 Annual General Meeting of Kuros Biosciences approves all resolutions https://ml-eu.globenewswire.com/media/ad3777c9-af1f-4b09-a899-3b3d6b8e962d/small/kuros-logo-jpg.jpg https://healthtimesrhodeisland.com/article/905898134-neuraclick-expands-scientific-and-translational-leadership-with-key-advisory-appointments Health Times of Rhode Island en PressRelease 2026-04-15T13:00:00+00:00 NeuraClick Expands Scientific and Translational Leadership with Key Advisory Appointments https://ml.globenewswire.com/media/04731e85-f435-4ef9-9077-b81361bf43f9/small/neuraclick-png-png.png https://healthtimesrhodeisland.com/article/905901024-dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-application-for-the-treatment-of-chemotherapy-induced-pain-and Health Times of Rhode Island en PressRelease 2026-04-15T13:00:00+00:00 Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy https://ml.globenewswire.com/media/7fe5cc47-6599-477c-a858-0f0d9b9f7eb5/small/green-and-gray-png.png https://healthtimesrhodeisland.com/article/905903583-alira-health-and-autoimmune-neurology-alliance-aina-launch-axis-registry-advancing-real-world-and-patient-centered-research-in-autoimmune-neurology Health Times of Rhode Island en PressRelease 2026-04-15T13:00:00+00:00 Alira Health and Autoimmune Neurology Alliance (AiNA) Launch AXIS Registry, Advancing Real-World and Patient-Centered Research in Autoimmune Neurology https://ml.globenewswire.com/media/c7422063-e642-4a37-86e3-d85294a19d12/small/alirahealth-jpg.jpg https://healthtimesrhodeisland.com/article/905898276-just-salad-expands-in-washington-d-c Health Times of Rhode Island en PressRelease 2026-04-15T12:57:00+00:00 Just Salad Expands in Washington, D.C. https://ml.globenewswire.com/media/c9572eec-3547-4c38-987c-8a46d1b438f5/medium/interior-mural-at-1919-pennsylvania-avenue-nw.jpg https://healthtimesrhodeisland.com/article/905903094-scientific-review-raises-questions-about-root-canal-safety-and-whole-body-health Health Times of Rhode Island en PressRelease 2026-04-15T12:50:00+00:00 Scientific Review Raises Questions About Root Canal Safety and Whole-Body Health https://ml.globenewswire.com/media/b6830cbc-f691-4b19-894a-b255e722ba81/medium/the-hidden-connection-root-canals-your-total-body-health.png https://healthtimesrhodeisland.com/article/905901148-pds-biotech-announces-publication-of-positive-pds01adc-interim-phase-2-clinical-trial-data-from-stage-1-of-nci-led-metastatic-colorectal-cancer-mcrc Health Times of Rhode Island en PressRelease 2026-04-15T12:45:00+00:00 PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial https://ml.globenewswire.com/media/e2e7d124-dbd4-4140-9cc5-449d3488a902/small/pds-biotech-logo-png.png https://healthtimesrhodeisland.com/article/905903520-vivos-therapeutics-schedules-release-of-full-year-2025-financial-results-and-conference-call Health Times of Rhode Island en PressRelease 2026-04-15T12:45:00+00:00 Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call https://ml.globenewswire.com/media/22d07f60-2e17-421d-bbc3-748c2402061e/small/picture2-jpg.JPG https://healthtimesrhodeisland.com/article/905899926-biosyent-to-present-at-2026-bloom-burton-co-healthcare-investor-conference Health Times of Rhode Island en PressRelease 2026-04-15T12:40:00+00:00 BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/3dded277-7953-4418-be63-7d7a3067811d/small/biosyent-logo-png.png https://healthtimesrhodeisland.com/article/905900740-inteleos-foundation-announces-2026-medmissions-award-to-advance-maternal-health-ultrasound-access-in-five-nations Health Times of Rhode Island en PressRelease 2026-04-15T12:38:00+00:00 Inteleos Foundation Announces 2026 MedMissions Award to Advance Maternal Health Ultrasound Access in Five Nations https://ml.globenewswire.com/media/MGI2ZWI4MGItOTIzNi00ZGFlLWIxNzAtNmI5MjJjOGZkNjA1LTEyNDUwMzItMjAyNi0wNC0xNS1lbg==/tiny/Inteleos-Inc-.png https://healthtimesrhodeisland.com/article/905898201-inspire-named-webby-awards-honoree-for-excellence-in-websites-mobile-sites-community Health Times of Rhode Island en PressRelease 2026-04-15T12:35:00+00:00 Inspire Named Webby Awards Honoree for Excellence in Websites & Mobile Sites - Community https://ml.globenewswire.com/media/ODg2MTE3YjktZWY4Yy00Y2U2LWI0MWUtYmY5MjYxYjQ2MWRlLTUwMDEyOTE4NC0yMDI2LTA0LTE1LWVu/tiny/Inspire.png https://healthtimesrhodeisland.com/article/905897330-healport-raises-1-2m-usd-to-scale-global-digital-health-infrastructure Health Times of Rhode Island en PressRelease 2026-04-15T12:30:00+00:00 HealPort Raises 1.2M USD to Scale Global Digital Health Infrastructure https://ml-eu.globenewswire.com/media/d6eb6ad3-be4e-40b6-944e-9fac4d976b1e/small/img-20251206-wa0000-jpg.jpg https://healthtimesrhodeisland.com/article/905898355-xenon-to-present-at-upcoming-investor-conferences Health Times of Rhode Island en PressRelease 2026-04-15T12:30:00+00:00 Xenon to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/505b89d3-dfd1-46e8-bc3b-3c9c699ef7ec/small/xenon-logo-tm-full-color-250x80px-png.png https://healthtimesrhodeisland.com/article/905901283-allogene-therapeutics-announces-nature-communications-publication-highlighting-pre-clinical-data-for-allo-329-a-next-generation-dual-targeted Health Times of Rhode Island en PressRelease 2026-04-15T12:30:00+00:00 Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://healthtimesrhodeisland.com/article/905899913-purchaser-business-group-on-health-unveils-results-of-2026-annual-member-survey-of-america-s-largest-employers Health Times of Rhode Island en PressRelease 2026-04-15T12:20:00+00:00 Purchaser Business Group on Health Unveils Results of ‘2026 Annual Member Survey’ of America’s Largest Employers https://ml.globenewswire.com/media/ZWE0Yjc4YjItYmYwNS00ZWVlLTllMjQtZDVjZjYwYjZmMmNkLTEyMTgzNzctMjAyNi0wNC0xNS1lbg==/tiny/Purchaser-Business-Group-on-He.png https://healthtimesrhodeisland.com/article/905902991-traws-pharma-announces-up-to-60-million-private-placement-financing Health Times of Rhode Island en PressRelease 2026-04-15T12:15:00+00:00 Traws Pharma Announces Up to $60 Million Private Placement Financing https://ml.globenewswire.com/media/1eb1780a-724e-4555-ab4d-455e27d18544/small/traws-pharma-blue-png.png https://healthtimesrhodeisland.com/article/905898273-billiontoone-to-report-first-quarter-2026-financial-results-on-may-6-2026 Health Times of Rhode Island en PressRelease 2026-04-15T12:05:00+00:00 BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026 https://ml.globenewswire.com/media/888ae54a-648f-4986-998b-84df416858c7/small/billion-to-one-logo-new-jpg.jpg https://healthtimesrhodeisland.com/article/905902765-scienture-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement Health Times of Rhode Island en PressRelease 2026-04-15T12:05:00+00:00 Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement https://ml.globenewswire.com/media/56382978-c242-4bdd-b491-e6966e27d4ed/small/logo-png.png https://healthtimesrhodeisland.com/article/905897683-ardena-opens-new-bioanalytical-laboratory-in-somerset-new-jersey Health Times of Rhode Island en PressRelease 2026-04-15T12:02:10+00:00 Ardena Opens New Bioanalytical Laboratory in Somerset, New Jersey https://ml-eu.globenewswire.com/media/cf6817f0-2603-46b6-aa6b-1cbb814079c4/medium/ardena-u-s-facility-in-somerset-new-jersey.png https://healthtimesrhodeisland.com/article/905898212-60-degrees-pharma-announces-arakoda-tafenoquine-for-malaria-prevention-is-now-available-on-runway-health-travel-website Health Times of Rhode Island en PressRelease 2026-04-15T12:02:00+00:00 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website https://ml.globenewswire.com/media/c950cab5-27b1-476f-befc-4d92a7389fdd/small/60degrees-logo-rgb-logo-jpg.jpg https://healthtimesrhodeisland.com/article/905897020-teva-launches-home-ground-schizophrenia-community-a-new-online-resource-hub-for-people-living-with-schizophrenia-and-their-care-partners Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://healthtimesrhodeisland.com/article/905897206-boehringer-ingelheim-and-zai-lab-announce-collaboration-on-dll3-targeting-t-cell-engager-and-adc-combination-in-small-cell-lung-cancer-and-other Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://healthtimesrhodeisland.com/article/905897922-folia-health-launches-brave-pws-study-to-better-understand-the-real-world-experience-of-prader-willi-syndrome-caregivers Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers https://ml.globenewswire.com/media/858e11f4-96a0-4321-93eb-d278df849ccf/small/untitled-design-1-png.png https://healthtimesrhodeisland.com/article/905898344-amarin-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-april-29-2026 Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 https://ml.globenewswire.com/media/00eeab93-e634-4279-86b3-7973c2a21623/small/amarin-logo-jpeg-jpg.jpg https://healthtimesrhodeisland.com/article/905898944-sab-bio-to-present-additional-data-supporting-the-unique-profile-of-sab-142-at-the-2026-immunology-of-diabetes-society-congress Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress https://ml.globenewswire.com/media/6d99a771-f2c9-4d05-bf57-4f6c070df032/small/sabprimarylogocolorrgb900px72ppi-png.png https://healthtimesrhodeisland.com/article/905899215-cue-biopharma-to-present-new-preclinical-data-on-lead-autoimmune-and-inflammatory-disease-candidate-cue-401-at-immunology2026 Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 https://ml.globenewswire.com/media/10541379-34cc-4869-a26f-fd99feead42a/small/cue-bio-brand-strategy-graphics-jpg.jpg https://healthtimesrhodeisland.com/article/905900529-picard-medical-syncardia-highlights-total-artificial-heart-bridge-to-transplant-case-at-texas-children-s-hospital Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Picard Medical / SynCardia Highlights Total Artificial Heart Bridge to Transplant Case at Texas Children's Hospital https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://healthtimesrhodeisland.com/article/905901251-beyond-air-to-participate-in-the-d-boral-capital-global-conference-2026 Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Beyond Air to Participate in the D. Boral Capital Global Conference 2026 https://ml.globenewswire.com/media/c7ae3957-2763-4e5c-9594-57e1ba60ed59/small/beyond-air-the-magic-of-breathing-png.png https://healthtimesrhodeisland.com/article/905901370-immutep-receives-fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma https://ml.globenewswire.com/media/b2cd55d0-59ab-45ac-a1fe-5cf2adac7f24/small/immutep-new-logo-png.png https://healthtimesrhodeisland.com/article/905901585-reviva-announces-letter-to-shareholders Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Reviva Announces Letter to Shareholders https://ml.globenewswire.com/media/1d8c6564-1da5-4561-b6ec-79de6d565869/small/reviva-logo-png.png https://healthtimesrhodeisland.com/article/905901758-calidi-biotherapeutics-announces-participation-in-redchip-s-april-16-virtual-investor-conference-to-feature-companies-advancing-clinical-pipelines-and Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://healthtimesrhodeisland.com/article/905902114-filana-therapeutics-announces-publication-in-epilepsia-of-preclinical-simufilam-data Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data https://ml.globenewswire.com/media/877131cb-f6f1-4b81-99c9-d2ea829a9272/medium/epilepsia-paper-figure-3c.png https://healthtimesrhodeisland.com/article/905902287-achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions https://ml.globenewswire.com/media/1026e030-275c-4391-8f9a-65c5c1ec7b88/small/achieve-logo-717x800px-2-1-jpg.jpg https://healthtimesrhodeisland.com/article/905902588-callio-therapeutics-to-present-poster-on-clio-8221-a-novel-dual-payload-antibody-drug-conjugate-at-aacr-2026 Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026 https://ml.globenewswire.com/media/3511fd62-eaba-4921-a3da-4e0b00d976e6/small/callio-logo-stacked-default-png.png https://healthtimesrhodeisland.com/article/905902871-extendicare-announces-april-2026-dividend-of-c-0-0441-per-share Health Times of Rhode Island en PressRelease 2026-04-15T12:00:00+00:00 Extendicare Announces April 2026 Dividend of C$0.0441 per Share https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg https://healthtimesrhodeisland.com/article/905902924-ai-enabled-fertility-care-and-longevity-provider-onto-health-closes-20-million-series-funded-by-artis-and-humania Health Times of Rhode Island en PressRelease 2026-04-15T11:52:00+00:00 AI-Enabled Fertility Care and Longevity Provider ONTO Health Closes $20 Million Series funded by ARTIS and Humania https://ml.globenewswire.com/media/bfd2a283-62a3-4223-a85d-f2bbd3a71ec6/small/16017175-5a43-4a1c-bd49-824adef1a0fb-png.png https://healthtimesrhodeisland.com/article/905880835-tilray-brands-accelerates-next-phase-of-global-growth-and-market-leadership Health Times of Rhode Island en PressRelease 2026-04-15T11:40:44+00:00 Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership https://ml.globenewswire.com/media/2dbf85bb-5e30-4623-8f9b-931442240c05/small/tilraybrands-logo-fullcolor-rbg-horiz-01-png.png https://healthtimesrhodeisland.com/article/905879486-inside-the-science-new-white-paper-explores-the-injection-set-to-redefine-the-treatment-of-knee-osteoarthritis-unlock-access-to-non-surgical Health Times of Rhode Island en PressRelease 2026-04-15T11:30:17+00:00 Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS https://ml-eu.globenewswire.com/media/OTcxNDdjMzktYjc5Yy00ODFkLWE3MGMtNDQyNDE5MGY5NjZiLTEzMjI2NDUtMjAyNi0wNC0xNS1lbg==/tiny/Contura-Orthopaedics-Ltd.png https://healthtimesrhodeisland.com/article/905879341-medicus-pharma-to-present-new-teverelix-data-at-aace-2026-demonstrating-long-acting-hormone-suppression Health Times of Rhode Island en PressRelease 2026-04-15T11:30:00+00:00 Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg https://healthtimesrhodeisland.com/article/905879590-brainsway-highlights-growing-u-s-payer-support-for-nurse-practitioner-administered-transcranial-magnetic-stimulation-tms-therapy Health Times of Rhode Island en PressRelease 2026-04-15T11:30:00+00:00 BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy https://ml.globenewswire.com/media/ea01c8f7-39be-46d2-a8e0-bc05994f170e/small/brainsway-2021-logo-jpg.jpg https://healthtimesrhodeisland.com/article/905879729-arbutus-receives-u-s-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b Health Times of Rhode Island en PressRelease 2026-04-15T11:30:00+00:00 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B https://ml.globenewswire.com/media/be474abd-3f6d-4270-a58e-1e6ee5c80bb2/small/arbutus-biopharma-logo.jpg https://healthtimesrhodeisland.com/article/905879994-plus-therapeutics-appoints-randy-h-goodman-phd-mha-as-vice-president-of-value-strategy-heor-to-advance-market-access-and-commercial-execution Health Times of Rhode Island en PressRelease 2026-04-15T11:30:00+00:00 Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://healthtimesrhodeisland.com/article/905880421-prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer Health Times of Rhode Island en PressRelease 2026-04-15T11:30:00+00:00 Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer https://ml.globenewswire.com/media/cab62748-b61a-42cb-b552-b0c6c91c4e83/small/ptx-logo-png.png https://healthtimesrhodeisland.com/article/905880501-tg-therapeutics-announces-completion-of-enrollment-for-the-phase-3-trial-evaluating-subcutaneous-briumvi Health Times of Rhode Island en PressRelease 2026-04-15T11:30:00+00:00 TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI https://ml.globenewswire.com/media/0e613f5f-8c22-4c63-a73b-c08cc0fbec64/small/tgtx-2021-logo.jpg https://healthtimesrhodeisland.com/article/905880748-clearmind-medicine-announces-positive-data-safety-monitoring-board-recommendation-in-ongoing-cmnd-100-clinical-trial Health Times of Rhode Island en PressRelease 2026-04-15T11:30:00+00:00 Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://healthtimesrhodeisland.com/article/905880639-alterity-therapeutics-to-host-virtual-kol-event-to-share-new-insights-on-ath434-for-the-treatment-of-multiple-system-atrophy Health Times of Rhode Island en PressRelease 2026-04-15T11:25:00+00:00 Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy https://ml.globenewswire.com/media/0771a9a2-2ac1-4a63-9767-a2b1df74af27/small/alterity-png.png https://healthtimesrhodeisland.com/article/905879871-stereotaxis-announces-definitive-agreement-to-acquire-robocath Health Times of Rhode Island en PressRelease 2026-04-15T11:00:00+00:00 Stereotaxis Announces Definitive Agreement to Acquire Robocath https://ml.globenewswire.com/media/95a5b8ca-b7c0-4c80-8ca7-063ef10706c3/small/stereotaxis-logo-new-tagline-black-text-png.png https://healthtimesrhodeisland.com/article/905879928-biocryst-to-report-first-quarter-2026-financial-results-on-may-6 Health Times of Rhode Island en PressRelease 2026-04-15T11:00:00+00:00 BioCryst to Report First Quarter 2026 Financial Results on May 6 https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://healthtimesrhodeisland.com/article/905880212-orvida-pharma-formerly-kamari-pharma-announces-favorable-phase-1a-safety-data-for-km-023-a-potential-first-in-disease-oral-trpv3-inhibitor-and Health Times of Rhode Island en PressRelease 2026-04-15T11:00:00+00:00 Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome https://ml.globenewswire.com/media/cd4d7fc1-6bca-4b1d-a6b3-2314ed21fb79/small/orvida-final-46-jpg.jpg https://healthtimesrhodeisland.com/article/905880223-tonix-pharmaceuticals-announces-publication-of-steady-state-pharmacokinetics-of-tonmya-after-20-days-of-daily-dosing-in-the-peer-reviewed-journal Health Times of Rhode Island en PressRelease 2026-04-15T11:00:00+00:00 Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development https://ml.globenewswire.com/media/16aad249-3d33-4501-b3d9-118a703fa46e/small/tonix2-jpg.jpg https://healthtimesrhodeisland.com/article/905880323-beeline-medicines-debuts-to-deliver-category-leading-precision-therapies-for-people-living-with-autoimmune-and-inflammatory-diseases Health Times of Rhode Island en PressRelease 2026-04-15T11:00:00+00:00 Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases https://ml.globenewswire.com/media/a870f826-b54c-4781-bf10-d8ce2db7245a/small/beelinemedicines-logo-fullcolor-png.png https://healthtimesrhodeisland.com/article/905880568-nrx-pharmaceuticals-advances-robotic-enabled-transcranial-magnetic-stimulation-combined-with-neuroplastic-therapy-for-military-and-first-responder Health Times of Rhode Island en PressRelease 2026-04-15T11:00:00+00:00 NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://healthtimesrhodeisland.com/article/905880425-neffy-epinephrine-nasal-spray-approved-in-canada-as-the-first-and-only-needle-free-emergency-treatment-of-allergic-reactions-anaphylaxis Health Times of Rhode Island en PressRelease 2026-04-15T10:05:00+00:00 neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) https://ml.globenewswire.com/media/8feeb9d1-ed0c-491a-988b-a2b54778e825/small/ars-logo-png.png https://healthtimesrhodeisland.com/article/905862956-alivecor-bringt-das-ki-gest-tzte-kardia-12l-in-europa-auf-den-markt-das-weltweit-erste-tragbare-12-kanal-ekg-mit-einzigartigem-ein-kabel-design Health Times of Rhode Island en PressRelease 2026-04-15T08:01:00+00:00 AliveCor bringt das KI-gestützte Kardia 12L in Europa auf den Markt: Das weltweit erste tragbare 12-Kanal-EKG mit einzigartigem Ein-Kabel-Design https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthtimesrhodeisland.com/article/905863061-alivecor-lanza-en-europa-el-kardia-12l-un-dispositivo-con-ia-el-primer-ecg-port-til-de-12-derivaciones-del-mundo-con-un-dise-o-nico-de-un-solo Health Times of Rhode Island en PressRelease 2026-04-15T08:01:00+00:00 AliveCor lanza en Europa el Kardia 12L, un dispositivo con IA: el primer ECG portátil de 12 derivaciones del mundo con un diseño único de un solo cable https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthtimesrhodeisland.com/article/905863140-lancement-par-alivecor-du-kardia-12l-aliment-par-l-ia-en-europe-le-premier-ecg-portable-12-d-rivations-au-monde-dot-d-une-conception-in-dite Health Times of Rhode Island en PressRelease 2026-04-15T08:01:00+00:00 Lancement par AliveCor du Kardia 12L alimenté par l’IA en Europe : le premier ECG portable à 12 dérivations au monde, doté d’une conception inédite à câble unique https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthtimesrhodeisland.com/article/905863200-alivecor-lancia-in-europa-kardia-12l-basato-su-intelligenza-artificiale-il-primo-ecg-portatile-a-12-derivazioni-al-mondo-con-un-esclusivo-design-a Health Times of Rhode Island en PressRelease 2026-04-15T08:01:00+00:00 AliveCor lancia in Europa Kardia 12L basato su intelligenza artificiale: il primo ECG portatile a 12 derivazioni al mondo con un esclusivo design a cavo singolo https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthtimesrhodeisland.com/article/905863241-alivecor-lanceert-de-ai-gestuurde-kardia-12l-in-europa-s-werelds-eerste-draagbare-12-afleidingen-ecg-met-een-uniek-ontwerp-met-n-kabel Health Times of Rhode Island en PressRelease 2026-04-15T08:01:00+00:00 AliveCor lanceert de AI-gestuurde Kardia 12L in Europa: 's werelds eerste draagbare 12-afleidingen-ECG met een uniek ontwerp met één kabel https://ml.globenewswire.com/media/ca97a5ad-9227-4559-a41a-59468d5bc246/small/alivecor-rgb-horizontal-blue-2-png.png https://healthtimesrhodeisland.com/article/905863456-alivecor-launches-ai-powered-kardia-12l-in-europe-the-world-s-first-handheld-12-lead-ecg-with-a-unique-single-cable-design Health Times of Rhode Island en PressRelease 2026-04-15T08:01:00+00:00 AliveCor Launches AI-Powered Kardia 12L in Europe: The World’s First Handheld 12-Lead ECG with a Unique Single-Cable Design https://ml.globenewswire.com/media/d510c9dc-7eb1-45bd-ba22-aa01f14d3e40/medium/alivecor-s-kardia-12l-launches-in-europe.png https://healthtimesrhodeisland.com/article/905862487-c-mo-medical-solutions-receives-ce-mark-for-its-novel-ai-powered-cough-monitoring-solution Health Times of Rhode Island en PressRelease 2026-04-15T08:00:00+00:00 C-mo Medical Solutions Receives CE Mark for Its Novel AI-Powered Cough Monitoring Solution https://ml-eu.globenewswire.com/media/MjJkZjIyNmItZDRjYi00MjIyLWI0ZTgtNGU4MzI0MjEyN2FiLTEwMzc0NTQtMjAyNi0wNC0xNS1lbg==/tiny/AKAMPION.png https://healthtimesrhodeisland.com/article/905843465-minervax-strengthens-executive-leadership-team-with-two-strategic-appointments-as-it-advances-its-maternal-gbs-vaccine-towards-pivotal-trial Health Times of Rhode Island en PressRelease 2026-04-15T07:30:00+00:00 MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation https://ml-eu.globenewswire.com/media/e8d7e6c7-c95d-4c2e-85d8-7c656c5ee8f5/small/minervax-logo-png.png https://healthtimesrhodeisland.com/article/905844405-notice-of-issuance-of-new-shares-in-connection-with-the-introduction-of-the-employee-stock-ownership-plan-matters-relating-to-stock-units-and Health Times of Rhode Island en PressRelease 2026-04-15T06:34:41+00:00 Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://healthtimesrhodeisland.com/article/905844939-clinuvel-advancing-peptides-for-photomedicine-and-vitiligo-care-at-aad-2026 Health Times of Rhode Island en PressRelease 2026-04-15T06:18:07+00:00 CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 https://ml.globenewswire.com/media/a63efa41-50f1-45f2-8ee5-0d54842edcaa/medium/clinuvels-pavilion-of-photomedicine-at-aad-2026.jpg https://healthtimesrhodeisland.com/article/905843826-aerska-strengthens-leadership-and-board-with-key-appointments-to-advance-systemically-delivered-rna-medicines-for-the-brain Health Times of Rhode Island en PressRelease 2026-04-15T06:00:00+00:00 Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain https://ml-eu.globenewswire.com/media/a4eb676a-dff5-4c91-a519-c5b46087f6f1/small/aerska-logo-1-png.png https://healthtimesrhodeisland.com/article/905843928-citryll-strengthens-intellectual-property-portfolio-with-grant-of-european-composition-of-matter-patent-for-cit-013 Health Times of Rhode Island en PressRelease 2026-04-15T06:00:00+00:00 Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013 https://ml-eu.globenewswire.com/media/34e26d4c-9c72-4edc-a853-633cca05b108/small/1-citryll-logo-rgb-002-png.png https://healthtimesrhodeisland.com/article/905824743-ose-immunotherapeutics-to-present-a-novel-first-in-class-fpr2-agonist-monoclonal-antibody-in-the-resolution-of-chronic-inflammation-at-the-aai-2026 Health Times of Rhode Island en PressRelease 2026-04-15T05:30:00+00:00 OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://healthtimesrhodeisland.com/article/905824755-ose-immunotherapeutics-pr-sentera-un-nouvel-anticorps-monoclonal-first-in-class-agoniste-de-fpr2-dans-la-r-solution-de-l-inflammation-chronique-au Health Times of Rhode Island en PressRelease 2026-04-15T05:30:00+00:00 OSE Immunotherapeutics présentera un nouvel anticorps monoclonal, first-in-class, agoniste de FPR2 dans la résolution de l’inflammation chronique au Congrès 2026 de l’AAI https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://healthtimesrhodeisland.com/article/905824846-bioversys-to-present-data-on-clinical-and-preclinical-pipeline-programs-at-escmid-global-2026 Health Times of Rhode Island en PressRelease 2026-04-15T05:00:00+00:00 BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026 https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://healthtimesrhodeisland.com/article/905824961-revolution-medicines-inc-prices-2-0-billion-in-concurrent-upsized-offerings-of-common-stock-and-convertible-senior-notes Health Times of Rhode Island en PressRelease 2026-04-15T04:41:13+00:00 Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://healthtimesrhodeisland.com/article/905808332-spyre-therapeutics-announces-pricing-of-upsized-403-0-million-public-offering-of-common-stock Health Times of Rhode Island en PressRelease 2026-04-15T02:38:25+00:00 Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://healthtimesrhodeisland.com/article/905808311-lecom-makes-pharmacy-education-more-accessible-with-three-fully-accredited-doctor-of-pharmacy-pathways Health Times of Rhode Island en PressRelease 2026-04-15T02:31:27+00:00 LECOM Makes Pharmacy Education More Accessible with Three Fully Accredited Doctor of Pharmacy Pathways https://ml.globenewswire.com/Resource/Download/53969c12-c282-4b1a-a914-4ac7480a61e3/image1.jpeg https://healthtimesrhodeisland.com/article/905790975-allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock Health Times of Rhode Island en PressRelease 2026-04-15T01:50:00+00:00 Allogene Therapeutics Announces Pricing of Public Offering of Common Stock https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png